Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort

Jade Ghosn (1) , Delphine Bachelet (2, 3, 1) , Marine Livrozet (4, 5, 6, 7) , Minerva Cervantes-Gonzalez (3, 1) , Julien Poissy (8) , François Goehringer (9) , Charlotte Salmon Gandonniere (10) , Mylène Maillet (11) , Firouzé Bani-Sadr (12) , Guillaume Martin-Blondel (13) , Pierre Tattevin (14, 15, 16) , Odile Launay (17) , Laure Surgers (18) , Emmanuel Dudoignon (19, 20, 21) , Geoffroy Liegeon (22) , David Zucman (23) , Cédric Joseph (24) , Eric Senneville (25) , Cécile Yelnik (26) , Pierre-Marie Roger (27, 28) , Karine Faure (29) , Marie Gousseff (30) , André Cabié (31, 32, 33) , Xavier Duval (34, 35) , Catherine Chirouze (36) , Cedric Laouénan (2)

1 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
2 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
3 CIC 1425 - Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique
4 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
5 CIC 1418 - CIC - HEGP
6 DMU CARTE - CArdiovasculaire Rénal Transplantation nEurovasculaire [Paris]
7 HEGP - Hôpital Européen Georges Pompidou [APHP]
8 UGSF - Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576
9 Service des Maladies Infectieuses et Tropicales [CHRU Nancy]
10 CIC - Centre d’Investigation Clinique [Tours] CIC 1415
11 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
12 CHU Reims - Hôpital universitaire Robert Debré [Reims]
13 Infinity - Institut Toulousain des Maladies Infectieuses et Inflammatoires
14 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
15 BRM - ARN régulateurs bactériens et médecine
16 CIC - Centre d'Investigation Clinique [Rennes]
17 CIC 1417 - CIC Cochin Pasteur
18 CHU Saint-Antoine [AP-HP]
19 MASCOT (UMR_S_942 / U942) - Marqueurs cardiovasculaires en situation de stress
20 Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
21 Cardiovascular & Renal Clinical Trialists - CRCT - French-Clinical Research Infrastructure Network - F-CRIN [Paris]
22 AP-HP - Hopital Saint-Louis [AP-HP]
23 Hôpital Foch [Suresnes]
24 AGIR - Agents infectieux, résistance et chimiothérapie - UR UPJV 4294
25 Centre Hospitalier Gustave Dron [Tourcoing]
26 EAS - European Atherosclerosis Society [Göteborg, Sweden]
27 CHU Pointe-à-Pitre/Abymes [Guadeloupe]
28 UA UFR SM - Université des Antilles - UFR des sciences médicales Hyacinthe Bastaraud
29 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
30 CHBA - Centre hospitalier Bretagne Atlantique (Morbihan)
31 CIC - Antilles Guyane - Centre d'Investigation Clinique Antilles-Guyane
32 CHU de la Martinique [Fort de France]
33 PCCEI - Pathogenesis and Control of Chronic and Emerging Infections
34 F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC)
35 CIC - CHU Bichat
36 LCE - Laboratoire Chrono-environnement (UMR 6249)

Objectives - Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort. Methods - Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender. Results - We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale <57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%). Conclusions - One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men.

Mots clés: Cohort; Emerging infectious diseases; Moderate to severe COVID-19; Post-acute COVID-19 symptoms; SARS-CoV-2; Cohort

Domaines: Médecine humaine et pathologie

Jade Ghosn, Delphine Bachelet, Marine Livrozet, Minerva Cervantes-Gonzalez, Julien Poissy, et al.. Prevalence of Post-Acute COVID-19 Symptoms Twelve Months after Hospitalisation in Participants Retained in Follow-up: Analyses Stratified by Gender from a Large Prospective Cohort. Clinical Microbiology and Infection, 2023, 29 (2), pp.254.e7-254.e13. ⟨10.1016/j.cmi.2022.08.028⟩. ⟨hal-03801797⟩